Fortress Biotech, Inc. (FBIO) intrinsic value & 10-year financials
Fortress Biotech, Inc. (FBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 15.7% a year to $61.2M, with an average return on invested capital of 1169.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.87
- Market cap
- $52.2M
- Revenue (FY2025)
- $61.2M
- Revenue growth (10-yr CAGR)
- 15.7%
- ROIC (10-yr avg)
- 1169.2%
- Free cash flow (FY2025)
- —
FBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $61.2M | $6.8M | -$0.07 | — | -114.7% | -190.4% |
| FY2024 | $55.1M | -$46.0M | -$2.69 | -$80.2M | -200.2% | -374.5% |
| FY2023 | $59.7M | -$60.6M | -$8.47 | -$128.3M | -238.6% | 11442.3% |
| FY2022 | $71.0M | -$86.6M | -$0.97 | -$182.1M | -286.7% | 260.3% |
| FY2021 | $63.1M | -$64.7M | -$0.79 | -$121.1M | -298.6% | 196.8% |
| FY2020 | $44.5M | -$46.5M | — | -$85.6M | -211.7% | 338.9% |
| FY2019 | $34.9M | -$40.0M | — | -$97.3M | -317.3% | -940.7% |
| FY2018 | $23.4M | -$84.1M | — | -$105.9M | -513.3% | -890.4% |
| FY2017 | $15.5M | -$66.9M | — | -$87.5M | -652.1% | 1513.6% |
| FY2016 | $16.5M | -$55.1M | — | -$52.2M | -398.7% | 335.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Fortress Biotech, Inc. is a consistent compounder, expanding top-line revenue at 15.7% annually over the past decade.
Fortress Biotech, Inc. returns on capital have been average, hovering around 11.7% ROIC over the decade.
Over the decade, Fortress Biotech, Inc. shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Fortress Biotech, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.33 per share.